Welcome to our dedicated page for ZIOP news (Ticker: ZIOP), a resource for investors and traders seeking the latest updates and insights on ZIOP stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ZIOP's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ZIOP's position in the market.
Ziopharm Oncology has appointed James Huang as Chairman of the Board, effective immediately. Huang, a board member since July 2020, brings over 20 years of experience in biotech and has founded companies like GenScript and Legend Biotech. Heidi Hagen is now the Lead Independent Director. The Board unanimously supported these elections, which are expected to strengthen leadership as the company advances its CAR-T and TCR technologies for cancer treatment.
BOSTON, Dec. 23, 2020 – Ziopharm Oncology (Nasdaq: ZIOP) announced that CEO Laurence Cooper will participate in the H.C. Wainwright Bioconnect 2021 Conference on January 11, 2021, and deliver a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021. The H.C. Wainwright event starts at 6:00 am ET, while the J.P. Morgan Conference begins at 8:20 am ET. Webcast presentations will be available via the Investors section of the Ziopharm website.
Ziopharm Oncology, Inc. (Nasdaq: ZIOP) announced that the Taiwan FDA has cleared an IND application from Eden BioCell for a phase 1 clinical trial of patient-derived CD19-specific CAR-T therapy. This innovative approach uses Rapid Personalized Manufacturing (RPM) technology, allowing for infusion one day after gene transfer. The trial aims to enroll up to 24 patients with relapsed CD19+ leukemias and lymphomas, evaluating safety and tolerability. The study leverages non-viral Sleeping Beauty technology and represents the first autologous CAR-T clinical study in Taiwan.
WaterMill Asset Management Corp. has successfully secured the necessary written consents to appoint Jaime Vieser and Holger Weis to Ziopharm Oncology's Board of Directors, reflecting strong shareholder support. Although both candidates will join due to the current Board cap of eight members, WaterMill also received consent to remove Scott Tariff from the Board. WaterMill emphasizes the importance of the additions at this critical time, stating they will enhance corporate governance and strategic initiatives aimed at generating near-term value for shareholders. This transition marks a significant refresh of board membership.
Ziopharm Oncology announces the election of Jaime Vieser and Holger Weis to its Board of Directors, following a consent solicitation by WaterMill Asset Management. Scott Tarriff, Chairman since 2018, has departed from the Board. The company expresses gratitude to shareholders for their feedback and highlights the focus on maximizing the potential of its pipeline. The full results of the consent solicitation will be disclosed in a Form 8-K filing with the SEC, and the company continues to develop innovative therapies for solid tumors.
Ziopharm Oncology (Nasdaq: ZIOP) announced that Chief Financial Officer Satyavrat Shukla intends to resign effective December 31, 2020, to pursue another opportunity. The company is actively searching for a new CFO. CEO Laurence Cooper praised Shukla's contributions, particularly in strengthening the firm's balance sheet and building a robust team. Ziopharm specializes in developing advanced therapies for cancer treatment using its innovative gene transfer platform.
WaterMill Asset Management announced its response to Ziopharm Oncology's recent campaign regarding a consent solicitation. WaterMill criticized Ziopharm's board appointments, claiming they reflect an anti-shareholder culture. They expressed concerns about the company's communication tactics and emphasized the importance of shareholders having their votes properly counted. WaterMill aims to support CEO Laurence Cooper in establishing better governance and a disciplined capital allocation policy if its slate is elected, urging shareholders to vote for their proposals by December 15, 2020.
Ziopharm Oncology (ZIOP) addressed a consent solicitation initiated by WaterMill Asset Management Corp. following a delay in the voting deadline, now set for December 15. The company urges shareholders to return the GREEN Consent Revocation Card, indicating doubts about WaterMill's shareholder support. Ziopharm's leadership reaffirms its commitment to shareholders and the development of solid tumor therapies. The firm is advancing its immuno-oncology strategies using non-viral and cytokine-driven therapies.
Ziopharm Oncology (Nasdaq: ZIOP) has responded to Egan-Jones Proxy Services' recommendation against the election of WaterMill's nominee Jaime Vieser to its Board. The company encourages shareholders to support its efforts by returning the GREEN Consent Revocation Card. Egan-Jones joins Institutional Shareholder Services in denouncing WaterMill's full slate of nominees, suggesting they do not benefit the company or shareholders. Analysts recognize Ziopharm's advancements in its therapy pipeline, emphasizing progress with its TCR-T, IL-12, and CAR-T programs.
WaterMill Asset Management, which holds approximately 3.3% of Ziopharm Oncology's shares, has launched a consent solicitation urging shareholders to vote for their proposed board candidates. WaterMill claims Ziopharm's current Board has mismanaged the company, leading to declining value and increasing expenses. They emphasize the urgency of electing their independent director candidates to restore financial health and governance. WaterMill's candidates are positioned as qualified solutions to counteract perceived governance failures at Ziopharm.
